APPENDIX 12: STUDIES IN THE NETWORK ANALYSIS - STUDY CHARACTERISTICS TABLES

6.6 PHARMACOLOGICAL INTERVENTIONS

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Anticonvulsants												
Gabapentin												
PANDE1999	USA	Clinical Interview (DSM-IV)	36	0.43	0.94	0	35	35	Pill placebo	N/A	21	14
							34	34	Gabapentin	NR	21	14
Levetiracetam												
ZHANG2005	USA	MINI (DSM-IV)	38	0.53	0.74	0	0	7	Pill placebo	N/A	14	7
							0	9	Levetiracetam	1139.5	14	7
Pregabalin												
FELTNER2011	USA	MINI (DSM-IV)	35	0.41	0.79	0	82	82	Pill placebo	N/A	21	11
							82	82	Pregabalin (600mg)	200	21	11
PANDE2004	USA	SCID (DSM-IV)	38	0.42	0.81	0	46	46	Pill placebo	N/A	21	10
							47	47	Pregabalin (600mg)	200	21	10
							42	42	Pregabalin (150mg)	50	21	10
PFIZER2007	BEL; GBR; ISR; NED; SWZ; USA; ZA	MINI (DSM-IV)	37	0.45	0.81	NR	97	79	Pill placebo	N/A	14	11
							95	70	Pregabalin (400mg)	200	14	11
							95	76	Paroxetine (20mg)	20	7	11
							87	71	Pregabalin (200mg)	100	14	11

Benzodiazapines												
Alprazolam												
GELERNTER1991	USA	ADIS (DSM-III)	37	0.63	0.91	0	15	15	Pill placebo	N/A	28	12
							15	12	Alprazolam	1.05	28	12
							15	13	Phenelzine	13.75	28	12
							20	17	CBT (Heimberg), group	2	1	12
Clonazepam												
DAVIDSON1993	USA	SCID (DSM III R)	37	0.43	0.99	0	36	33	Pill placebo	N/A	14	10
							39	37	Clonazapam	1.2	14	10
KNIJNIK2008	BRA	MINI (DSM-IV)	33	0.61	NR	0	29	28	Clonazapam	0.74	14	12
							29	29	Psychodynamic Psychotherapy	1.5	1	12
									Clonazapam	0.645	14	12
MUNJACK1990	USA	SCID (DSM III R)	33	0.75	0.8	0	11	10	No treatment	N/A	N/A	8
							12	10	Clonazapam	2.75	7	8
OTTO2000	USA	SCID (DSM III R)	40	0.4	NR	0	25	25	Clonazapam	NR	14	12
							20	20	CBT (Heimberg), group	2.5	1	12
Monoamine Oxidase Inhibitors (MAOIs)												
Moclobemide												
BURROWS1997	AUS; AUT; BEL; BRA; CAN; FRA;	SCID (DSM-IV)	36	0.43	NR	0	0	194	Pill placebo	N/A	7	12
							0	193	Moclobemide	600	7	12
							NR	191	Moclobemide	300	7	12

	GER; GBR; ISL; NED; SWE; SWZ											
OOSTERBAAN2001	NED	SCID (DSM III R)	37	0.42	NR	0	27	19	Pill placebo	N/A	7	15
							27	24	Moclobemide	589	7	15
							28	24	CBT, individual	0.75	1	15
PRASKO2003	CZE	NR	28	0.52	NR	NR	0	20	Moclobemide	NR	NR	26
							0	24	CBT, individual	NR	NR	26
									Pill placebo	N/A	NR	26
							NR	22	CBT, individual	NR	NR	26
									Moclobemide	NR	NR	26
SCHNEIER1998	USA	SCID (DSM III R)	35	0.4	0.8	0	37	37	Pill placebo	N/A	14	8
							40	40	Moclobemide	364	14	8
STEIN2002a	ZA	SCID (DSM-IV)	34	0.47	NR	0	193	189	Pill placebo	N/A	7	12
							191	188	Moclobemide	315	14	12
VERSIANI1992	BRA	SCID (DSM III R)	0	NR	NR	0	0	26	Pill placebo	N/A	7	8
							0	26	Moclobemide	580.7	7	8
							NR	26	Phenelzine	67.5	7	8
Phenelzine												
BLANCO2010	USA	Clinical Interview (DSM-IV)	32	0.41	0.48	0	39	27	Pill placebo	N/A	7	12
							45	35	Phenelzine	65.9	7	12
							40	34	CBT (Heimberg), group	2.5	1	12
							42	32	CBT	2.5	1	12

									(Heimberg), group			
									Phenelzine	62	7	12
GELERNTER1991	USA	ADIS (DSM-III)	37	0.63	0.91	0	15	15	Pill placebo	N/A	28	12
							15	12	Alprazolam	1.05	28	12
							15	13	Phenelzine	13.75	28	12
							20	17	CBT (Heimberg), group	2	1	12
HEIMBERG1998	USA	SCID (DSM III R)	35	0.5	NR	0	33	26	Psychological placebo	NR	1	12
							33	27	Pill placebo	N/A	7	12
							31	26	Phenelzine	NR	7	12
							36	28	CBT (Heimberg), group	2.5	1	12
LIEBOWITZ1990	USA	Clinical Interview (DSM-III)	34	0.31	NR	0	28	26	Pill placebo	N/A	7	8
							28	23	BB, Atenolol	97.6	7	8
							29	25	Phenelzine	75.7	7	8
VERSIANI1992	BRA	SCID (DSM III R)	0	NR	NR	0	0	26	Pill placebo	N/A	7	8
							0	26	Moclobemide	580.7	7	8
							NR	26	Phenelzine	67.5	7	8
Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)												
Venlafaxine												
STEIN2005	USA	MINI (DSM-IV)	37	0.42	0.89	0	134	126	Pill placebo	N/A	7	28
							131	119	Venlafaxine (<75mg/day)	72.2	7	28
							130	119	Venlafaxine (>75mg/day)	213.7	7	28
ALLGULANDER2004	FRA; FIN; NOR;	MINI (DSM-IV)	39	0.53	NR	NR	146	132	Pill placebo	N/A	7	12
							144	128	Paroxetine (40mg)	42.4	7	12

	SWE; USA						144	129	Venlafaxine (>75mg/day)	192.4	7	12
LIEBOWITZ2005a	USA	MINI (DSM-IV)	35	0.45	0.8	NR	140	133	Pill placebo	N/A	7	12
							139	138	Venlafaxine (>75mg/day)	165	7	12
LIEBOWITZ2005b	USA	MINI (DSM-IV)	36	0.46	0.71	0	147	144	Pill placebo	N/A	7	12
							147	136	Paroxetine (40mg)	46	7	12
							146	133	Venlafaxine (>75mg/day)	201.7	7	12
RICKELS2004	USA	MINI (DSM-IV)	41	0.43	0.97	0	0	135	Pill placebo	N/A	7	12
							0	126	Venlafaxine (>75mg/day)	178	7	12
Selective Serotonin Reuptake Inhibitors (SSRIs)												
Citalopram												
FURMARK2002	SWE	SCID (DSM-IV)	35	0.44	1	0	6	6	Wait list	N/A	N/A	9
							6	6	Citalopram	40	7	9
							6	6	CBT, group	3	0.9	9
FURMARK2005	SWE	SCID (DSM-IV)	32	0.53	NR	NR	12	12	Pill placebo	N/A	7	6
							12	12	NK1A	5	7	6
							12	12	Citalopram	40	7	6
Escitalopram												
KASPER2005	AUT; CAN; DEN; FIN; GBR; GER; NOR; RSA	MINI (DSM-IV)	38	0.45	NR	0	177	176	Pill placebo	N/A	7	12
							181	177	Escitalopram	17.6	7	12
LADER2004	Multiple	MINI (DSM-IV)	37	0.53	0.99	0	166	164	Pill placebo	N/A	7	24
							170	162	Escitalopram	20	7	24

							167	162	Escitalopram (10mg)	10	7	24
							167	166	Escitalopram (5mg)	5	7	24
							169	166	SS, Paroxetine (20mg)	20	7	24
Fluoxetine												
CLARK2003	GBR	SCID (DSM-IV)	33	0.52	NR	0	20	20	Exposure instructions	0.6	1	16
									Pill placebo	N/A	7	16
							20	20	Exposure instructions	0.6	1	16
									Fluoxetine	60	7	16
							20	20	CT (Clark & Wells), individual	1.25	1	16
DAVIDSON2004b	USA	SCID (DSM-IV)	37	0.46	0.78	0	60	60	Pill placebo	N/A	7	14
							57	57	Fluoxetine	43.6	7	14
							60	60	CBT, group	1	1	14
							59	59	CBT, group	1	1	14
									Pill placebo	N/A	7	14
							59	59	CBT, group	1	1	14
									Fluoxetine	47.3	7	14
KOBAK2002	USA	SCID (DSM-IV)	39	0.58	NR	NR	30	30	Pill placebo	N/A	7	14
							30	30	Fluoxetine	50	7	14
Fluvoxamine												
ASAKURA2007	JPN	Clinical Interview (DSM-IV)	39	0.32	NR	NR	89	89	Pill placebo	N/A	7	10
							182	176	Fluvoxamine	225	7	10
DAVIDSON2004a	USA	SCID (DSM-IV)	37	0.36	0.78	0	140	126	Pill placebo	N/A	7	12
							139	121	Fluvoxamine	174	7	12

STEIN1999	USA	SCID (DSM-IV)	39	0.36	NR	0	44	44	Pill placebo	N/A	7	12
							48	42	Fluvoxamine	202	7	12
VAN-VLIET1994	NED	Clinical Interview (DSM-III R)	35	0.57	NR	0	14	13	Pill placebo	N/A	7	12
							16	15	Fluvoxamine	150	7	12
WESTENBERG2004	FRA; GBR; GER; IRL; NED; RSA; USA	SCID (DSM-IV)	38	0.52	NR	0	151	148	Pill placebo	N/A	7	12
							149	146	Fluvoxamine	209	7	12
Paroxetine												
ALLGULANDER1999	SWE	Clinical Interview (DSM-IV)	39	NR	NR	0	48	48	Pill placebo	N/A	7	12
							48	44	Paroxetine	NR	7	12
ALLGULANDER2004	FRA; FIN; NOR; SWE; USA	MINI (DSM-IV)	39	0.53	NR	NR	146	132	Pill placebo	N/A	7	12
							144	128	Paroxetine (40mg)	42.4	7	12
							144	129	Venlafaxine (>75mg/day)	192.4	7	12
BALDWIN1999	BEL; ESP; FRA; GBR; GER; IRL; RSA	MINI (DSM-IV)	36	0.54	0.89	0	151	151	Pill placebo	N/A	7	12
							139	139	Paroxetine	34.7	7	12
GLAXOSMITHKLINE2006	JPN	NR	37	0.52	0	NR	133	130	Pill placebo	N/A	7	12
							132	132	Paroxetine (20mg)	20	7	12
							135	133	Paroxetine	40	7	12

									(40mg)			
LADER2004	Multiple	MINI (DSM-IV)	37	0.53	0.99	0	166	164	Pill placebo	N/A	7	24
							170	162	Escitalopram	20	7	24
							167	162	Escitalopram (10mg)	10	7	24
							167	166	Escitalopram (5mg)	5	7	24
							169	166	Paroxetine (20mg)	20	7	24
LEPOLA2004	Europe; ZA	MINI (DSM-IV)	39	0.5	0.94	0	186	184	Pill placebo	N/A	7	12
							189	186	Paroxetine	32.3	7	12
LIEBOWITZ2002	CAN; USA	SCID (DSM-IV)	37	0.41	0.82	NR	95	92	Pill placebo	N/A	7	12
							97	89	Paroxetine (20mg)	20	7	12
							95	88	Paroxetine (40mg)	40	7	12
							97	91	Paroxetine (60mg)	60	7	12
LIEBOWITZ2005b	USA	MINI (DSM-IV)	36	0.46	0.71	0	147	144	Pill placebo	N/A	7	12
							147	136	Paroxetine (40mg)	46	7	12
							146	133	Venlafaxine (>75mg/day)	201.7	7	12
PFIZER2007	BEL; GBR; ISR; NED; SWZ; USA; ZA	MINI (DSM-IV)	37	0.45	0.81	NR	97	79	Pill placebo	N/A	14	11
							95	70	Pregabalin (400mg)	200	14	11
							95	76	Paroxetine (20mg)	20	7	11
							87	71	Pregabalin (200mg)	100	14	11
SEEDAT2004	USA	SCID (DSM-IV)	31	0.21	NR	0	14	14	Paroxetine	38.9	1	10
									Pill placebo	N/A	14	10

							14	14	Paroxetine	40	1	10
									Clonazapam	1	14	10
STEIN1998	CAN; USA	SCID (DSM-IV)	36	0.53	0.53	0	93	92	Pill placebo	N/A	7	12
							94	90	Paroxetine	36.6	7	12
Sertraline												
BLOMHOFF2001	NOR; SWE	Clinical Interview (DSM-IV)	40	0.6	NR	NR	95	88	Pill placebo	N/A	7	24
							98	91	Exposure instructions	0.3	0.7	12
									Pill placebo	N/A	7	24
							96	87	Sertraline	120.1	7	24
							98	88	Exposure instructions	0.3	0.7	12
									Sertraline	120.1	7	24
LIEBOWITZ2003	USA	SCID (DSM-IV)	35	0.4	0.72	0	204	196	Pill placebo	N/A	7	12
							211	205	Sertraline	158.8	7	12
VAN-AMERINGEN2001	CAN	SCID (DSM-IV)	36	0.44	0.93	0	69	69	Pill placebo	N/A	7	20
							135	134	Sertraline	146.7	7	20
Other Pharmacological Interventions												
Atenolol (Beta-antagonist)												
LIEBOWITZ1990	USA	Clinical Interview (DSM-III)	34	0.31	NR	0	28	26	Pill placebo	N/A	7	8
							28	23	Atenolol	97.6	7	8
							29	25	Phenelzine	75.7	7	8
Atomoxetine (NRI)												
RAVINDRAN2009	USA	ND: LSAS	42	0.22	0.85	0	13	12	Pill placebo	N/A	7	10
							14	13	Atomoxetine	78.6	7	10
Mirtazapine												
SCHUTTERS2010	NED	MINI (DSM-IV)	39	0.57	NR	0	30	30	Pill placebo	N/A	7	12
							30	30	Mirtazapine	45	7	12
NK_1-A												
FURMARK2005	SWE	SCID (DSM-IV)	32	0.53	NR	NR	12	12	Pill placebo	N/A	7	6
							12	12	NK_1A	5	7	6

							12	12	Citalopram	40	7	6
Paroxetine combined with Clonazepam												
SEEDAT2004	USA	SCID (DSM-IV)	31	0.21	NR	0	14	14	Paroxetine	38.9	1	10
									Pill placebo	N/A	14	10
							14	14	Paroxetine	40	1	10
									Clonazapam	1	14	10
St John's Wort												
KOBAK2005	USA	NR	37	0.51	0.93	0	21	20	Pill placebo	N/A	14	12
							20	20	St John's Wort	838	14	12

6.7 PSYCHOLOGICAL INTERVENTIONS

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Individual Cognitive Behavioural Therapy (CBT)												
COTTRAUX2000	FRA	Clinical Interview (DSM-IV)	34	0.59	NR	0	28	28	Supportive Therapy	30	0.5	12
							27	27	CBT, individual	1.7	1.2	12
EMMELKAMP2006	NED	SCID (DSM-IV)	34	0.52	NR	NR	18	16	Wait list	N/A	N/A	20
							23	22	Psychodynamic Psychotherapy	0.75	1	20
GOLDIN2012	USA	ADIS (DSM-IV)	33	0.46	0.57	0	37	37	Wait list	N/A	N/A	16
							38	38	CBT (Heimberg), individual	1	1	16
HERBERT2004	USA	SCID (DSM-IV)	34	0.44	0.77	NR	15	15	CBT, individual	1	1	12
							19	19	CBT, individual (18wk)	1	0.7	18
LEDLEY2009	USA	ADIS (DSM-IV)	35	0.58	0.79	0.26	22	19	Wait list	0.25	0.5	20
							16	15	CBT (Heimberg), individual	1.03	1	20
OOSTERBAAN2001	NED	SCID (DSM III R)	37	0.42	NR	0	27	19	Pill placebo	N/A	7	15
							27	24	Moclobemide	589	7	15
							28	24	CBT, individual	0.75	1	15
PRASKO2003	CZE	NR	28	0.52	NR	NR	0	20	Moclobemide	NR	NR	26
							0	24	CBT,	NR	NR	26

									individual			
ROBILLARD2010	CAN	Clinical Interview (DSM-IV)	35	0.71	NR	NR	15	15	Wait list	N/A	N/A	16
							16	16	CBT, individual	NR	NR	16
							14	14	CBT, individual (VR exposure)	NR	NR	16
Individual Cognitive Therapy (CT)												
CLARK2003	GBR	SCID (DSM-IV)	33	0.52	NR	0	20	20	Exposure instructions	0.58	1	16
									Pill placebo	N/A	7	16
							20	20	Exposure instructions	0.58	1	16
									Fluoxetine	60	7	16
							20	20	CT (Clark & Wells), individual	1.25	1	16
CLARK2006	GBR	ADIS (DSM-IV)	32	0.44	0.89	0.28	20	20	Wait list	N/A	N/A	14
							21	21	Exposure (In vivo)	1.5	1	14
							21	21	CT (Clark & Wells), individual	1.5	1	14
CLARK2012	GBR	ADIS (DSM-IV)	33	NR	NR	0.28	27	27	Wait list	N/A	N/A	14
							28	28	CT (Clark & Wells), individual	1.5	1	14
							27	27	CT (Clark & Wells), individual (with self-study)	1.5	0.5	14

							21	18	CBT, individual	0.75	1	20
LEICHSENRING2012	GER	SCID (DSM-IV)	35	0.55	NR	0	79	79	Wait list	N/A	N/A	0
							207	207	Pychodynamic Psychotherapy	1	1	26
MORTBERG2007	SWE	SCID (DSM-IV)	35	0.63	NR	NR	33	33	Treatment as usual	N/A	N/A	3
							35	35	CBT, group	5.13	2.67	3
							32	32	CT (Clark & Wells), individual shortened	1	1	17
									Pill placebo	N/A	NR	26
							NR	22	CBT, individual	NR	NR	26
									Moclobemide	NR	NR	26
STANGIER2003	GER	SCID (DSM-IV)	39	0.49	NR	0.05	37	21	Wait list	N/A	N/A	43
							32	22	CBT, group	2	1	15
							26	22	CT (Clark & Wells), individual shortened	1	1	15
STANGIER2011	GER	SCID (DSM-IV)	36	0.56	NR	0	41	39	Wait list	0.83	0.8	20
							38	36	Interpersonal Psychotherapy	0.83	0.8	20
							38	36	CT (Clark & Wells), individual shortened	0.83	0.8	20
Group Cognitive Behavioural Therapy (CBT)												
Heimberg model												
BLANCO2010	USA	Clinical	32	0.41	0.48	0	39	27	Pill placebo	N/A	7	12

		Interview (DSM-IV)					45	35	Phenelzine	65.9	7	12
							40	34	CBT group	2.5	1	12
							42	32	CBT group	2.5	1	12
									Phenelzine	62	7	12
GELERNTER1991	USA	ADIS (DSM-III)	37	0.63	0.91	0	15	15	Pill placebo	N/A	28	12
							15	12	Alprazolam	1.05	28	12
							15	13	Phenelzine	13.75	28	12
							20	17	CBT group	2	1	12
GRUBER2001	GER; USA	ADIS (DSM-III R)	42	0.52	NR	0.17	18	17	Wait list	N/A	N/A	12
							18	14	CBT group	2.5	1	12
							18	15	CBT group (with self-study)	2.5	0.67	12
HEDMAN2011	Sweden	SCID (DSM-IV)	35	0.36	NR	0.25	64	64	Self-help (internet) with support	N/A	N/A	15
							62	62	CBT group	2.5	1	15
HEIMBERG1990	USA	ADIS (DSM-III)	30	0.45	NR	NR	24	20	Psychological placebo	2	1	12
							25	20	CBT group	2	1	12
HEIMBERG1998	USA	SCID (DSM III R)	35	0.5	NR	0	33	26	Psychological placebo	NR	1	12
							33	27	Pill placebo	N/A	7	12
							31	26	Phenelzine	NR	7	12
							36	28	CBT group	2.5	1	12
HERBERT2005	USA	SCID (DSM-IV)	34	0.57	0.65	0.23	30	30	CBT group	2	1	12
							35	35	CBT group (with social skills)	2	1	12
HOPE1995	USA	ADIS (DSM-III R)	34	0.5	NR	0.3	11	10	Wait list	N/A	N/A	12
							11	10	Exposure (In vivo)	2.25	1	12

							18	13	CBT group	2.25	1	12
KOSZYCKI2007	CAN	MINI (DSM-IV)	38	0.53	NR	0.28	26	26	Mindfulness	2.5	1	8
							27	27	CBT group	2.5	1	12
OTTO2000	USA	SCID (DSM III R)	40	0.4	NR	0	25	25	Clonazapam	NR	14	12
							20	20	CBT group	2.5	1	12
WONG2006	CHI	NR	35	0.41	0	1	17	17	Wait list	N/A	N/A	10
							17	17	CBT group	2.5	1	10
Group CBT (not Heimberg model)												
ALDEN2011	CAN	ADIS (DSM-IV)	34	0.41	NR	0.38	25	23	Wait list	N/A	N/A	12
							31	27	CBT (enhanced), group	2	1	12
ANDREWS2011	AUS	NR	32	0.41	NR	NR	23	14	Self-help (internet) with support	0.05	0.75	8
							14	11	CBT, group	4	1	7
BJORNSSON2011	USA	Clinical Interview (DSM-IV)	20	0.47	0.89	0	0	23	Psychological placebo	2	1	8
							0	22	CBT, group	2	1	8
BORGEAT2009	SWZ	Clinical Interview (DSM-IV)	40	0.53	NR	NR	15	13	Exposure (In vivo)	2.5	1	8
							15	14	CBT, group	2.5	1	8
DAVIDSON2004b	USA	SCID (DSM-IV)	37	0.46	0.78	0	60	60	Pill placebo	N/A	7	14
							57	57	Fluoxetine	43.6	7	14
							60	60	CBT, group	1	1	14
							59	59	CBT, group	1	1	14
									Pill placebo	N/A	7	14
							59	59	CBT, group	1	1	14
									Fluoxetine	47.3	7	14
FURMARK2002	SWE	SCID (DSM-IV)	35	0.44	1	0	6	6	Wait list	N/A	N/A	9
							6	6	Citalopram	40	7	9

							6	6	CBT, group	3	0.89	9
MATTICK1988	AUS	Clinical Interview (DSM-III)	37	0.53	1	NR	26	23	Exposure (In vivo)	2	1	6
							25	21	CBT, group	2	1	6
MATTICK1989	AUS	Clinical Interview (DSM-III)	42	0.53	NR	NR	10	8	Wait list	N/A	N/A	6
							11	10	Exposure (In vivo)	2	1	6
							11	9	Cognitive Restructuring	2	1	6
							11	10	CBT, group	2	1	6
MCEVOY2009	AUS	Clinical Interview (DSM-IV)	31	0.37	NR	0.56	36	30	CBT, group	4	1	7
							39	30	CBT, group (with attention training)	4	1	7
MORGAN1999	AUS	Clinical Interview (DSM-III R)	32	0.47	NR	0.47	16	14	CBT, group	8	3.33	3
							20	16	CBT, group (with safety behaviours)	8	3.33	3
MORTBERG2007	SWE	SCID (DSM-IV)	35	0.63	NR	NR	33	33	Treatment as usual	N/A	N/A	3
							35	35	CBT, group	5.13	2.67	3
							32	32	CT (Clark & Wells), individual shortened	1	1	17
PIET2010	DEN	ADIS (DSM-IV)	22	0.69	NR	0	14	14	Mindfulness	2	1	8
							12	12	CBT, group	2	1	14
RAPEE2007	AUS	ADIS (DSM-IV)	36	0.51	NR	0.32	52	52	Wait list	N/A	N/A	12
							56	56	Self-help (book) no support	N/A	N/A	12
							59	59	CBT, group	2	0.83	12

							57	57	CBT, group (with self-study)	2	0.42	12
RAPEE2009	AUS	ADIS (DSM-IV)	34	0.52	NR	0.27	58	56	Psychological placebo	2	1	12
							66	59	CBT, group	2	1	12
							71	68	CBT, group (enhanced exposure)	2	1	12
SALABERRIA1998	ESP	ADIS (DSM-III R)	31	0.48	1	NR	23	20	Wait list	0	0	8
							24	18	Exposure (In vivo)	2.5	1	8
							24	18	CBT, group	2.5	1	8
STANGIER2003	GER	SCID (DSM-IV)	39	0.49	NR	0.05	37	21	Wait list	N/A	N/A	43
							32	22	CBT, group	2	1	15
							26	22	CT (Clark & Wells), individual shortened	1	1	15
Exercise												
JAZAIERI2012	USA	ADIS (DSM-IV)	34	0.52	0.56	0	25	18	Exercise	NR	NR	8
							31	24	Mindfulness	2.5	1	8
Exposure (In vivo)												
ANDERSSON2006	SWE	SCID (DSM-IV)	37	0.52	NR	0.22	32	32	Wait list	N/A	N/A	9
							32	30	Exposure (In vivo)	3	1	2
									Self-help (book) no support	N/A	N/A	9
BORGEAT2009	SWZ	Clinical Interview (DSM-IV)	40	0.53	NR	NR	15	13	Exposure (In vivo)	2.5	1	8
							15	14	CBT, group	2.5	1	8

CLARK2006	GBR	ADIS (DSM-IV)	32	0.44	0.89	0.28	20	20	Wait list	N/A	N/A	14
							21	21	Exposure (In vivo)	1.5	1	14
							21	21	CT (Clark & Wells), individual	1.5	1	14
HOPE1995	USA	ADIS (DSM-III R)	34	0.5	NR	0.3	11	10	Wait list	N/A	N/A	12
							11	10	Exposure (In vivo)	2.25	1	12
							18	13	CBT (Heimberg), group	2.25	1	12
MATTICK1988	AUS	Clinical Interview (DSM-III)	37	0.53	1	NR	26	23	Exposure (In vivo)	2	1	6
							25	21	CBT, group	2	1	6
MATTICK1989	AUS	Clinical Interview (DSM-III)	42	0.53	NR	NR	10	8	Wait list	N/A	N/A	6
							11	10	Exposure (In vivo)	2	1	6
							11	9	Cognitive Restructuring	2	1	6
							11	10	CBT, group	2	1	6
SALABERRIA1998	ESP	ADIS (DSM-III R)	31	0.48	1	NR	23	20	Wait list	0	0	8
							24	18	Exposure (In vivo)	2.5	1	8
							24	18	CBT, group	2.5	1	8
SMITS2006	USA	CIDI (DSM-IV)	22	0.57	0.77	NR	15	15	Psychological placebo	1.25	3	1
							23	18	Exposure (In vivo)	1.25	3	1
							20	17	Exposure (In vivo), audience	1.25	3	1

									feedback			
							19	18	Exposure (In vivo), performance feedback	1.25	3	1
STRAVYNSKI2000	CAN	ADIS (DSM-IV)	38	0.58	NR	NR	32	28	Social skills training	2	1	12
							36	32	Exposure (In vivo)	2	1	12
Interpersonal psychotherapy												
LIPSITZ2008	USA	Clinical Interview (DSM-IV)	35	0.43	0.5	NR	34	26	Supportive Therapy	NR	1	14
							36	26	Interpersonal Psychotherapy	NR	1	14
STANGIER2011	GER	SCID (DSM-IV)	36	0.56	NR	0	41	39	Wait list	0.83	0.8	20
							38	36	Interpersonal Psychotherapy	0.83	0.8	20
							38	36	CT (Clark & Wells), individual shortened	0.83	0.8	20
Mindfulness												
JAZAIERI2012	USA	ADIS (DSM-IV)	34	0.52	0.56	0	25	18	Exercise	NR	NR	8
							31	24	Mindfulness	2.5	1	8
KOSZYCKI2007	CAN	MINI (DSM-IV)	38	0.53	NR	0.28	26	26	Mindfulness	2.5	1	8
							27	27	CBT (Heimberg), group	2.5	1	12
PIET2010	DEN	ADIS (DSM-IV)	22	0.69	NR	0	14	14	Mindfulness	2	1	8
							12	12	CBT, group	2	1	14
Short-term psychodynamic psychotherapy												
EMMELKAMP2006	NED	SCID	34	0.52	NR	NR	18	16	Wait list	N/A	N/A	20

		(DSM-IV)					23	22	Psychodynamic Psychotherapy	0.75	1	20
							21	18	CBT, individual	0.75	1	20
KNIJNIK2008	BRA	MINI (DSM-IV)	33	0.61	NR	0	29	28	Clonazapam	0.74	14	12
							29	29	Psychodynamic Psychotherapy	1.5	1	12
									Clonazapam	0.645	14	12
LEICHSENRING2012	GER	SCID (DSM-IV)	35	0.55	NR	0	79	79	Wait list	N/A	N/A	0
							207	207	Psychodynamic Psychotherapy	1	1	26
							209	209	CT (Clark & Wells), individual shortened	1	1	26
Social skills training												
STRAVYNSKI2000	CAN	ADIS (DSM-IV)	38	0.58	NR	NR	32	28	Social skills training	2	1	12
							36	32	Exposure (In vivo)	2	1	12
Supportive therapy												
COTTRAUX2000	FRA	Clinical Interview (DSM-IV)	34	0.59	NR	0	28	28	Supportive Therapy	30	0.5	12
							27	27	CBT, individual	1.7	1.2	12
LIPSITZ2008	USA	Clinical Interview (DSM-IV)	35	0.43	0.5	NR	34	26	Supportive Therapy	NR	1	14
							36	26	Interpersonal Psychotherapy	NR	1	14

Self-help with or without support												
Self-help without support												
CHUNG2008	KOR	ADIS (DSM-IV)	26	0.4	NR	NR	18	14	Wait list	N/A	N/A	6
							12	11	Self-help (book) no support	N/A	N/A	6
							15	13	Self-help (book) with support	N/A	N/A	6
FURMARK2009a	Sweden	SCID (DSM-IV)	36	0.68	NR	0.67	40	40	Wait list	N/A	N/A	9
							40	40	Self-help (book) no support	N/A	1	9
							40	40	Self-help (internet) with support	N/A	1	9
FURMARK2009b	Sweden	SCID (DSM-IV)	35	0.68	NR	0.14	29	29	Self-help (book) no support	N/A	1	9
							28	28	Self-help (book) with discussion group	N/A	1	9
							29	29	Self-help (internet) with support	N/A	1	9
							29	29	Self-help (internet) with support (applied relaxation)	N/A	1	9
RAPEE2007	AUS	ADIS	36	0.51	NR	0.32	52	52	Wait list	N/A	N/A	12

		(DSM-IV)					56	56	Self-help (book) no support	N/A	N/A	12
							59	59	CBT, group	2	0.8	12
							57	57	CBT, group (with self-study)	2	0.4	12
TITOV2008c	AUS	MINI (DSM-IV R)	38	0.61	NR	0.22	35	34	Wait list	N/A	N/A	10
							31	30	Self-help (internet) no support	N/A	N/A	10
							32	31	Self-help (internet) with support	N/A	N/A	10
TITOV2009b	AUS	MINI (DSM-IV)	41	0.52	NR	0.22	84	82	Self-help (internet) no support	N/A	N/A	8
							84	81	Self-help (internet) with support	N/A	N/A	8
TITOV2010b	AUS	MINI (DSM-IV)	44	0.47	NR	0.16	56	55	Self-help (internet) no support	N/A	N/A	8
							57	53	Self-help (internet) no support (with motivational enhancement)	N/A	N/A	8
Self-help with support												
ABRAMOWITZ2009	USA	MINI (DSM-IV)	43	0.76	1	0.57	10	10	Wait list	N/A	N/A	8
							11	11	Self-help (book) with	N/A	N/A	8

									support			
ANDERSSON2012	SWE	SCID (DSM-IV)	38	0.6	NR	0.14	102	102	Wait list	N/A	N/A	9
							102	102	Self-help (internet) with support	N/A	N/A	9
ANDREWS2011	AUS	NR	32	0.41	NR	NR	23	14	Self-help (internet) with support	0.05	0.75	8
							14	11	CBT, group	4	1	7
BERGER2009	SWZ	SCID (DSM-IV)	29	0.56	NR	NR	21	21	Wait list	N/A	N/A	10
							31	31	Self-help (internet) with support	N/A	N/A	10
CARLBRING2007	Sweden	SCID (DSM-IV R)	33	0.62	NR	NR	30	28	Wait list	N/A	N/A	8
							30	29	Self-help (internet) with support	N/A	N/A	8
CHUNG2008	KOR	ADIS (DSM-IV)	26	0.4	NR	NR	18	14	Wait list	N/A	N/A	6
							12	11	Self-help (book) no support	N/A	N/A	6
							15	13	Self-help (book) with support	N/A	N/A	6
FURMARK2009a	Sweden	SCID (DSM-IV)	36	0.68	NR	0.67	40	40	Wait list	N/A	N/A	9
							40	40	Self-help (book) no support	N/A	1	9
							40	40	Self-help (internet) with support	N/A	1	9
FURMARK2009b	Sweden	SCID	35	0.68	NR	0.14	29	29	Self-help	N/A	1	9

		(DSM-IV)							(book) no support			
							28	28	Self-help (book) with discussion group	N/A	1	9
							29	29	Self-help (internet) with support	N/A	1	9
							29	29	Self-help (internet) with support (applied relaxation)	N/A	1	9

HEDMAN2011	Sweden	SCID (DSM-IV)	35	0.36	NR	0.25	64	64	Self-help (internet) with support	N/A	N/A	15
							62	62	CBT (Heimberg), group	2.5	1	15
TITOV2008a	AUS	CIDI (DSM-IV R)	38	0.59	NR	0.3	55	49	Wait list	N/A	N/A	10
							50	50	Self-help (internet) with support	N/A	N/A	10
TITOV2008b	AUS	CIDI (DSM-IV R)	37	0.63	NR	0.26	45	40	Wait list	N/A	N/A	10
							43	41	Self-help (internet) with support	N/A	N/A	10
TITOV2008c	AUS	MINI (DSM-IV	38	0.61	NR	0.22	35	34	Wait list	N/A	N/A	10
							31	30	Self-help	N/A	N/A	10

		R)							(internet) no support			
							32	31	Self-help (internet) with support	N/A	N/A	10
TITOV2009a	AUS	MINI (DSM-IV)	39	0.56	NR	0.28	42	39	Self-help (internet) with support	N/A	N/A	8
							43	43	Self-help (internet) with support (discussion group)	N/A	N/A	8
TITOV2009b	AUS	MINI (DSM-IV)	41	0.52	NR	0.22	84	82	Self-help (internet) no support	N/A	N/A	8
							84	81	Self-help (internet) with support	N/A	N/A	8

HEDMAN2011	Sweden	SCID (DSM-IV)	35	0.36	NR	0.25	64	64	Self-help (internet) with support	N/A	N/A	15
							62	62	CBT (Heimberg), group	2.5	1	15
TITOV2008a	AUS	CIDI (DSM-IV R)	38	0.59	NR	0.3	55	49	Wait list	N/A	N/A	10
							50	50	Self-help (internet) with support	N/A	N/A	10
TITOV2008b	AUS	CIDI (DSM-IV	37	0.63	NR	0.26	45	40	Wait list	N/A	N/A	10
							43	41	Self-help (internet)	N/A	N/A	10

		R)							with support			
TITOV2008c	AUS	MINI (DSM-IV R)	38	0.61	NR	0.22	35	34	Wait list	N/A	N/A	10
							31	30	Self-help (internet) no support	N/A	N/A	10
							32	31	Self-help (internet) with support	N/A	N/A	10
TITOV2009a	AUS	MINI (DSM-IV)	39	0.56	NR	0.28	42	39	Self-help (internet) with support	N/A	N/A	8
							43	43	Self-help (internet) with support (discussion group)	N/A	N/A	8
TITOV2009b	AUS	MINI (DSM-IV)	41	0.52	NR	0.22	84	82	Self-help (internet) no support	N/A	N/A	8
							84	81	Self-help (internet) with support	N/A	N/A	8

6.8 COMBINED PSYCHOLOGICAL AND PHARMACOLOGICAL INTERVENTIONS

Study	Country	Interview	Age	% Female	% White	% Med	N Rand	N Post	Group	Dose	Freq	Dur
Group CBT with fluoxetine												
DAVIDSON2004b	USA	SCID (DSM-IV)	37	0.46	0.78	0	60	60	Pill placebo	N/A	7	14
							57	57	Fluoxetine	43.6	7	14
							57	57	Fluoxetine	43.6	7	14
							60	60	CBT, group	1	1	14
							59	59	CBT, group	1	1	14
									Pill placebo	N/A	7	14
							59	59	CBT, group	1	1	14
									Fluoxetine	47.3	7	14
Group CBT with phenelzine												
BLANCO2010	USA	Clinical Interview (DSM-IV)	32	0.41	0.48	0	39	27	Pill placebo	N/A	7	12
							45	35	Phenelzine	65.9	7	12
							40	34	CBT (Heimberg), group	2.5	1	12
							42	32	CBT (Heimberg), group	2.5	1	12
									Phenelzine	62	7	12
Individual CBT with moclobemide												
PRASKO2003	CZE	NR	28	0.52	NR	NR	0	20	Moclobemide	NR	NR	26
							0	24	CBT, individual	NR	NR	26
									Pill placebo	N/A	NR	26
							NR	22	CBT, individual	NR	NR	26
									Moclobemide	NR	NR	26
Psychodynamic therapy with clonazepam												

KNIJNIK2008	BRA	MINI (DSM-IV)	33	0.61	NR	0	29	28	Clonazapam	0.74	14	12
							29	29	Psychodynamic Psychotherapy	1.5	1	12
									Clonazapam	0.645	14	12

Country: Three letter abbreviations for all countries from which participants were recruited.
Interview: If a structured interview was used, the same of the interview and the diagnostic criteria used.
Age: Mean age of participants.
% **Female**: Percentage of participants enrolled who were female.
% **White**: Percentage of participants enrolled who described themselves white/Caucasian.
% **Med**: Percentage of participants taking medication (e.g. SSRI or benzodiazepine) at baseline. Normally these participants were on a stable dose and agreed not to change their dose during the trial.
N Rand: Number of participants randomised to each group.
N Post: Number of participants who completed assessment at post-treatment.
Group: Name of each group included in the trial.
Dose: For each group, the amount of medication or psychological intervention received. For medication, milligrams per dose (average where possible, otherwise endpoint). For psychological interventions, hours per dose.
Freq: Number of doses per week.
Dur: Number of weeks of intervention. Dose x Freq X Dur = Total amount of medication or psychological intervention received.